Netherlands calling with a 10% discount on C5's Pharma & Biotech Patent Litigation Conference

This Kat has never really been to Amsterdam
- Schiphol Airport does not count. So she was excited to learn that this year's C5 Pharma and Biotech Patent Litigation Conference is being held in Amsterdam on 23-24 May 2023. This year's session - no surprise - delves into what litigation in the new era of the UPC will look like for pharma and biotech litigation. 

The sessions include
  • Interview with Judges Rian Kalden (Senior Judge, Court of Appeal, The Hague) and Margot Kokke (Dstirct Court Judge, The Hague) from the UPC 
  • Tactical Training Session for UPC Litigators: Developing Offensive and Defensive Strategies for Success 
  • ADR in the UPC: Preparing for the New UPC Patent Mediation and Arbitration Centre (PMAC) 
  • Forecast the Future of Plausibility and Priority in Light of the Latest EBA Referral Cases 
  • Prepare for Anticipated Reform of the EU’s General Pharmaceutical Legislation 
  • Develop Transnational Tactics for Avoiding and Defending Contributory and Induced Infringement Claims 
  • Formulate Winning Global Strategies for Biosimilars and Biologics Patent Litigation
The Agenda can be found here.   The AmeriKat is particularly looking forward to the session on "Managing the Implications of the EPO's Decisions in BOA Referral G 2/21" and, as ever, her favorite favorite topic - SPCs.  She will be reporting from the event, so look out for posts for those who are unable to attend.  However, if you can swing it, it is going to be a great couple of days of debate and discussion as we embark upon a new age of European patent litigation. 

The IPKat is pleased to offer a 10% discount for all IPKat readers who mention the code code D10-630-630FX01.
Netherlands calling with a 10% discount on C5's Pharma & Biotech Patent Litigation Conference Netherlands calling with a 10% discount on C5's Pharma & Biotech Patent Litigation Conference Reviewed by Annsley Merelle Ward on Friday, May 12, 2023 Rating: 5

No comments:

All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.

It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.

Learn more here:

Powered by Blogger.